Use of a novel bone graft substitute in peri-articular bone tumours of the knee.
We treated three patients with aneurysmal bone cysts and seven with giant cell tumours who presented with a large osteolytic lesion in peri-articular areas of the knee. The patients age ranged from 8 to 49 years (mean 25 years). The average tumour volume was measured at 39.8 cm(3) (range 18 to 65 cm(3)). The tumour cavities were treated with curettage, phenolisation and application of a composite bone graft substitute containing 35% calcium-sulphate hemihydrate and 65% hydroxyapatite granules. All patients were followed up for 4.0 to 5.2 years (mean 4.5 years). Tumour recurrence was noted in two cases. In the remaining patients consolidation of the lesion was considered complete at a mean of 4.5 months (3-6.5 months). During follow-up no deformities developed and no radiological signs of joint degeneration were noted. All patients regained close to normal function, with a mean Musculoskeletal Tumour Society Rating Score of 95.1%. Due to their good osteoconductive abilities, composite synthetic bone graft substitute combining porous hydroxyapatite with calcium-sulphate appears to be an effective alternative to autologous cancellous bone graft in the treatment of large osteolytic lesions in peri-articular areas around the knee joint. They bear major advantages through ubiquitous availability and the avoidance of morbidity associated with iliac crest harvest. Concerns remain as the radio-opaque appearance of the bone graft substitute may potentially delay the detection of tumour recurrence.
Schindler
Oliver S
OS
Droitwich Knee Clinic, Droitwich Spa, Worcestershire, England, UK. schindler@doctors.net.uk
Cannon
Stephen R
SR
Briggs
Timothy W R
TW
Blunn
Gordon W
GW
D000328:Adult; D017824:Bone Cysts, Aneurysmal / Q000601:surgery; D001859:Bone Neoplasms / Q000601:surgery*; D018786:Bone Substitutes / Q000008:administration & dosage*; D002133:Calcium Sulfate / Q000008:administration & dosage*; D002648:Child; D017886:Durapatite / Q000008:administration & dosage*; D005260:Female; D005269:Femur / Q000601:surgery*; D005500:Follow-Up Studies; D018212:Giant Cell Tumor of Bone / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D013977:Tibia / Q000601:surgery*; D016896:Treatment Outcome
D018786:Bone Substitutes; D017886:Durapatite; D002133:Calcium Sulfate